Last reviewed · How we verify
Sugammadex Injection [Bridion]
Sugammadex is a selective relaxant binding agent that encapsulates and inactivates rocuronium and vecuronium neuromuscular blocking agents, rapidly reversing neuromuscular blockade.
Sugammadex is a selective relaxant binding agent that encapsulates and inactivates rocuronium and vecuronium neuromuscular blocking agents, rapidly reversing neuromuscular blockade. Used for Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults undergoing surgery, Reversal of deep neuromuscular blockade in anesthetized patients.
At a glance
| Generic name | Sugammadex Injection [Bridion] |
|---|---|
| Also known as | Sugammadex |
| Sponsor | University Health Network, Toronto |
| Drug class | Selective relaxant binding agent |
| Target | Rocuronium and vecuronium (steroidal neuromuscular blocking agents) |
| Modality | Small molecule |
| Therapeutic area | Anesthesia |
| Phase | FDA-approved |
Mechanism of action
Sugammadex works by forming a tight 1:1 complex with steroidal neuromuscular blocking agents (rocuronium and vecuronium), removing them from the neuromuscular junction and plasma. This mechanism allows rapid reversal of neuromuscular blockade without the need for acetylcholinesterase inhibitors, providing faster and more reliable recovery of neuromuscular function compared to traditional reversal agents.
Approved indications
- Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults undergoing surgery
- Reversal of deep neuromuscular blockade in anesthetized patients
Common side effects
- Nausea
- Vomiting
- Headache
- Hypotension
- Tachycardia
- Cough
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sugammadex Injection [Bridion] CI brief — competitive landscape report
- Sugammadex Injection [Bridion] updates RSS · CI watch RSS
- University Health Network, Toronto portfolio CI